Jan. 17, 2014
/PRNewswire/ -- CVS Caremark (NYSE: CVS) today announced that it has completed the acquisition of Coram LLC ("Coram"), the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. Coram is one of the nation's largest providers of comprehensive infusion services, caring for approximately 165,000 patients annually. Coram has 4,600 employees, including 600 nurses, 350 pharmacists and 250 dietitians, operating primarily through 85 branch locations and six centers of excellence for patient intake.
"With the acquisition of Coram, we have expanded our competitive offerings in specialty services," said
, President of CVS Caremark Pharmacy Services. "From a capabilities perspective, no other organization brings the range of specialty assets, the depth of experience and integration of care that the combination of CVS Caremark and Coram can deliver."
With Coram, CVS Caremark will have comprehensive resources to more effectively manage the cost of specialty drugs, including infused therapies, whether they are covered through the medical or the pharmacy benefit. For patients this means better clinical outcomes, while payors will see lower total health care costs.
The acquisition is consistent with CVS Caremark's goal of investing in core businesses that help drive growth. Coram is expected to generate approximately
in revenues during the first twelve months following the close of the deal. Including one-time transaction and integration costs, as well as the interest associated with the
of senior notes issued to fund this transaction, the transaction is expected to have an immaterial impact on CVS Caremark's overall financial results in 2014. The transaction is expected to add
$0.03 to $0.05 cents
to the Company's Adjusted Earnings Per Share in 2015, the first full year following the close of the deal.
Barclays served as the Company's financial advisor on the transaction, while Sullivan and Cromwell LLP served as legal advisor, and Dechert LLP served as legal advisor from an anti-trust perspective.